The Council today adopted conclusions on COVID-19. The conclusions welcome the EU’s effective response to the challenges arising from the outbreak of Novel coronavirus and urge member states to take the necessary measures to enhance their cooperation. They also call on the Commission to examine ways of facilitating member states’ access to personal protective equipment and to evaluate the consequences of global health threats for the availability of medicines within the EU.
By European Federation of Pharmaceutical Industries and Associations
The pharmaceutical industry in Europe has worked to support the EU27 and UK to reach an agreement that will allow patients to receive medicines and medical technologies without disruption and provide long term co-operation between the EU and the UK in areas such as research, clinical trials, pharmacovigilance and access to talent. Our industry’s stance remains that the EU and UK should have the closest possible relationship for pharmaceuticals, prioritising the health of citizens and the uninterrupted supply of medicines.
By European Medicines Verification Organisation
The EMVS protects patients from the risk of falsified medicines through an end-to-end verification of medicinal packs.
Update: the report from the meeting is now available.
By Lung Cancer Europe
Lung cancer is responsible for nearly 1 in 5 cancer related deaths in Europe, yet it remains a cancer that is underfunded and underrepresented. Previous research has demonstrated that many people impacted by lung cancer face disparities in access to diagnostics, treatment and care.
To mark World Cancer Day, LuCE has released its latest position paper which identifies disparities and challenges in access to lung cancer diagnostics and treatment across Europe. Data were collected through 34 healthcare professionals/researchers, 16 pharmaceutical companies and LuCE members (patient organizations).